SRR934905
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 88.53482260183968
- age_years
- 46
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934771 | — | — | 0.984 |
| 2 | SRR934972 | — | — | 0.961 |
| 3 | SRR934959 | — | — | 0.948 |
| 4 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.936 |
| 5 | SRR934810 | — | — | 0.936 |
| 6 | SRR934973 | — | — | 0.934 |
| 7 | 065d8d7a-c241-4a24-8f77-2cb5a4341f35 | — | — | 0.920 |
| 8 | BS_4W68NV3M | medulloblastoma | — | 0.920 |
| 9 | BS_QRDT19KS | medulloblastoma | — | 0.919 |
| 10 | SRR650166 | — | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.273 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.203 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.156 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.122 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.076 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.015 | Remibrutinib | — uncovered |